A Comparative Bioavailability and Bioequivalence Study of Two Dosage Formulations of an Investigational Medicinal Product in Healthy Adults for Migraine Management

The primary objective is to evaluate the bioequivalence between two different dosage formulations of the investigational medicinal product. This comparison is essential to ensure that both formulations provide equivalent systemic exposure in healthy adults. There are no secondary objectives reported.

The sponsor did not provide information regarding the total number of participants. The study population consists of healthy volunteers, including both male and female individuals. The age range corresponds to children and adolescents. Participants may have a history of migraine with or without aura. The study population includes vulnerable groups.

This Phase 2 clinical trial is designed as a comparative study to evaluate the blood levels of two different dosage formulations of a study medicine in healthy adults. The research methodology aims to compare the pharmacokinetic properties of the formulations. The study sequence begins with a screening visit to assess eligibility. Following screening, participants will undergo scheduled study visits to monitor the administration of the medicine and subsequent physiological responses. The clinical course concludes with an end-of-study visit. The total duration of the study is estimated to occur between May 2026 and August 2026. Participation may be subject to early termination based on predefined clinical criteria or safety protocols.

The assessment of efficacy in this study involves evaluating the impact of the intervention on migraine with or without aura. The evaluation focuses on the primary and secondary parameters related to the clinical manifestation and frequency of the condition.